Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05002127 · ClinicalTrials.gov registry record · Phase 2

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

A Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma, sponsored by ALX Oncology.

Active
Registry status
Phase 2
Development phase
127
Enrollment target
20
Study locations

NCT05002127: Active Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma, sponsored by ALX Oncology.

NCT05002127 is a Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma that is active but no longer recruiting, run by ALX Oncology. The registered enrollment target is 127 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05002127, a Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma, is active but no longer recruiting, sponsored by ALX Oncology.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
127 participants
Enrollment target
20
Study locations

Study Summary

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Primary Outcome

Percentage of patients with objective response per RECIST 1.1

Conditions Studied

Gastric Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

Interventions

  • DRUG Trastuzumab
  • DRUG Paclitaxel
  • DRUG Evorpacept (ALX148)
  • DRUG Ramucirumab

Study Locations (20)

Other

  • Universitair Ziekenhuis Antwerpen - Antwerp
  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg - Leuven
  • Centre Hospitalier Universitaire de Liège - Liège
  • Fakultní Nemocnice Hradec Králové - Hradec Králové
  • Fakultní Nemocnice Olomouc - Olomouc
  • Vseobecna Fakultni Nemocnice v Praze - Prague
  • Centre Hospitalier Régional et Universitaire de Besançon - Hôpital Jean-Minjoz - Besançon
  • Centre Hospitalier Universitaire de Bordeaux - Bordeaux
  • Hôpital Morvan - Brest
  • Centre Léon Bérard - Lyon
  • Hôpital Privé Jean Mermoz - Lyon
  • Institut Paoli-Calmettes - Marseille
  • Hôpital Saint-Antoine - Paris

California

  • The Oncology Institute of Hope & Innovation - Anaheim
  • University of California Los Angeles - Los Angeles

Tennessee

  • Vanderbilt University Medical Center - Nashville

Virginia

  • NEXT Virginia - Fairfax

Washington

  • Fred Hutchinson Cancer Center - Seattle

Queensland

  • Icon Cancer Centre Southport - Southport

Victoria

  • Monash Medical Centre - Clayton

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2022-01-15
Est. Completion 2026-06
Phase Phase 2
ALX Oncology

9 total trials

What the registry record for NCT05002127 still lists

NCT05002127 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (60% lower).

The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 4 interventions - of which Trastuzumab is the first listed.

NCT05002127 names 20 study sites across 7 states, led by Other, California, Tennessee.

Frequently Asked Questions

What is clinical trial NCT05002127 about?

NCT05002127 is a clinical study titled "A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)". A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

What is the current status of trial NCT05002127?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2022-01-15. Estimated completion is 2026-06.

What conditions does trial NCT05002127 study?

This clinical trial studies the following conditions: Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.

What interventions are being tested in trial NCT05002127?

The interventions under investigation include: Trastuzumab (DRUG), Paclitaxel (DRUG), Evorpacept (ALX148) (DRUG), Ramucirumab (DRUG).

Who is sponsoring clinical trial NCT05002127?

This trial is sponsored by ALX Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05002127 being conducted?

This trial has 20 study locations across California, Tennessee, Virginia, Washington, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05002127's enrollment target sits among peer trials

127 73rd of 153 higher than 81 of 153 other Gastric Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03017820 · 127 participants · Phase 1

    A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

  • NCT03609580 · 127 participants · Phase 1

    Post-operative Urinary Retention (POUR) Following Thoracic Surgery

  • NCT06285643 · 127 participants · Phase 2

    A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

  • NCT06809400 · 127 participants · Phase 1

    A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05002127, the US trial registry maintained by the National Library of Medicine. NCT05002127 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.